{
    "organizations": [],
    "uuid": "a6805d8e1c109b8b9f3dc0cfe4c1910b33db053c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-verona-pharma-says-positive-top-li/brief-verona-pharma-says-positive-top-line-data-from-phase-2b-trial-of-rpl554-idUSFWN1R7027",
    "ord_in_thread": 0,
    "title": "BRIEF-Verona Pharma Says Positive Top-Line Data From Phase 2B Trial Of RPl554",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Verona Pharma Plc:\n* VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2B CLINICAL TRIAL OF RPL554 FOR MAINTENANCE TREATMENT OF COPD\n* PRIMARY ENDPOINT MET; RPL554 PRODUCED CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN LUNG FUNCTION AT ALL DOSES\n* VERONA PHARMA - CLINICALLY RELEVANT SECONDARY ENDPOINTS WERE ALSO MET, INCLUDING STATISTICALLY SIGNIFICANT, PROGRESSIVE IMPROVEMENTS IN COPD SYMPTOMS\n* RPL554 WAS WELL TOLERATED AT ALL DOSE LEVELS IN THIS FOUR WEEK 400 PATIENT STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-26T14:30:00.000+03:00",
    "crawled": "2018-03-27T11:55:01.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "verona",
        "pharma",
        "plc",
        "verona",
        "pharma",
        "report",
        "positive",
        "data",
        "phase",
        "2b",
        "clinical",
        "trial",
        "rpl554",
        "maintenance",
        "treatment",
        "copd",
        "primary",
        "endpoint",
        "met",
        "rpl554",
        "produced",
        "clinically",
        "statistically",
        "significant",
        "improvement",
        "lung",
        "function",
        "dos",
        "verona",
        "pharma",
        "clinically",
        "relevant",
        "secondary",
        "endpoint",
        "also",
        "met",
        "including",
        "statistically",
        "significant",
        "progressive",
        "improvement",
        "copd",
        "symptom",
        "rpl554",
        "well",
        "tolerated",
        "dose",
        "level",
        "four",
        "week",
        "patient",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}